Sustainability Data Summary 2020 - AstraZeneca

1 Sustainability Data Summary 2020 AstraZeneca Data Summary 2020 Targets for healthy people, healthy planet and healthy businessSustainability at AstraZeneca is about using our capabilities to make the most meaningful impact where society needs it health. We know the health of people, the planet and our business are interconnected, each impacting the targets serve as our path forward to achieve sustainable growth. The mindset of improving our performance means learning from the lessons of the past, building on our prior goals and adapting periodically to achieve a more prosperous describe our targets and progress for our priorities in this report . We continue to manage other aspects of our strategy, which span many parts of our is a supplement to our 2020 Sustainability report , which is available at Independent external assurance was provided by Bureau Veritas as described in the Sustainability letter of Nations Sustainable Development Goals (SDGs)The SDGs are a universal call to action to ensure that all people live fulfilling and prosperous lives by 2030.

2 They represent the collective actions the world can take to address the most pressing issues inequality, injustice, poverty, climate change we face as a global community. While we recognise that our business impacts all 17 SDGs, we evaluate our contribution by connecting our metrics to the SDG s underlying targets. We have indicated this throughout the report in the SDG column of the and transparency15 Ethical business culture 15 inclusion and diversity 17 Talent and workforce evolution 18 Workforce wellbeing and safety 19 Responsible supply chain 20 Human rights 22 Additional areas 23 Environmental protection6 Product environmental stewardship6 Greenhouse gas reduction 7 Pharmaceuticals in the environment 11 Water stewardship 12 Waste management 13 Environmental compliance 14 Access to healthcare 3 Access to healthcare (including Investment in health systems) 3 Disease prevention and treatment 4 Affordability 5We recognise that several of our measures (or annual KPIs)

3 Were impacted by the pandemic and may not reflect a typical science can doDisease understandingConnecting broader omic-technologies can identify the more complex and transient molecular changes that underpin the course of disease. AstraZeneca is turning this data into knowledge, to help identify novel drug image:Environmental protectionEthics and transparencyAccess to healthcare2 TargetsHighlightsPeople reached12025 targetReach 50 million people (cumulatively) through Healthy Heart Africa, Young Health Programme (YHP), Healthy Lung and Phakamisa updateMore than 25 million people reached (cumulatively) through Healthy Heart Africa, YHP, Phakamisa and Healthy Lung programmes. This target has been modified to double the people reached and now encompasses four Access to healthcare programmes. Status: On planHealthcare workers trained12025 targetTrain 170,000 healthcare workers (cumulatively) to strengthen health systems throughout the world through our Healthy Heart Africa, Healthy Lung, Phakamisa programmes and Young Health updateMore than 132,000 healthcare workers trained (cumulatively).

4 The previous target of 75,000 was achieved in : On plan Access to healthcare (including Investment in health systems)KPIsPeople reached by access to healthcare programmes (cumulative), million2 SDG201820192020 Healthy Heart Africa Lung Asia4 Lung Lung Mexico Lung Saudi Lung Health PEOPLE REACHED (all programmes) facilities activated (cumulative)SDG201820192020 Healthy Heart Lung Asia4 ,6462,055 Healthy Lung Lung Lung Saudi Lung (all programmes) ,0022,8953,363 Healthcare workers trained (cumulative)SDG201820192020 Healthy Heart Africa3c5,8187,2807,361 Phakamisa Physicians and Nurses33c762762762 Phakamisa Navigator Volunteers33c523523523 Healthy Lung Asia43c26,12157,56279,806 Healthy Lung Gulf53c5402,2834,783 Healthy Lung Mexico3c5841,1351,135 Healthy Lung Saudi Arabia73c1,54015,93817,012 Healthy Lung Egypt83cN/A330330 Young Health Programme3c18,821920,345920,533 TOTAL (all programmes)3c54,709106,158132,2452018201 92020106,000+132,000+54,000+Healthy Heart millionPeople reached by Access to healthcare programmes (cumulative)Healthcare workers trained (cumulative)Healthy millionPlease see more information on Data Summary 2020 Environmental protectionEthics and transparencyAccess to healthcare3 Key Performance Indicators (KPIs) Young Health Programme (additional KPIs on page 3)

5 SDG201820192020 Active markets151824 Peer educators trained (cumulative) 56,741963,8269118,841 AstraZeneca HealthCare Foundation s Connections for Cardiovascular HealthSM (cumulative)10201820192020 Total amount given in grants (USD million) tracked for progress59,87765,42267,513US-based non-profits funded525258 Care in Cambodia (cumulative)SDG201820192020 Women screened in the ,8445,6876,174 Women diagnosed with breast cancer and enrolled in the programme578660718 Units of medicines administered through the programme11235,081265,270295,447 Healthcare workers trained 3c1,2281,2721,292 TargetsHighlightsYoung Health Programme (YHP) Active markets2020 targetMaintain YHP in current active markets and expand into two new updateOur YHP has reached 24 markets. We launched new programmes in two countries and accelerator programmes in six countries.

6 Status: AchievedDisease prevention and treatment15 markets18 markets24 markets201820192020 Six new markets addedActive markets4 AstraZeneca Data Summary 2020 Environmental protectionEthics and transparencyAccess to healthcare4 AffordabilityKPIsAffordability1220182019 2020 People reached by Patient Assistance Programmes (cumulative, million) donation through Patient Assistance Programmes13 (USD, million) , 1 The target was updated in 2020 due to inclusion of YHP data into total cumulative numbers. 2 People reached is defined per programme, depending on the operations: Healthy Heart Africa includes the number of blood pressure screenings; Phakamisa includes the number of women reached through early breast cancer detection and awareness; Healthy Lung Asia methodology updated from 2017 people reached includes only those diagnosed or educated or treated.

7 3 Phakamisa was placed on hold during 2020 due to contract expiry with NGO partner. The programme was relaunched in November 2020. Data expected from 2021. 4 2019 Healthy Lung Asia data has been updated with data received post 2019 Data Summary publication 5 With exception of healthcare workers trained, all other Healthy Lung Gulf activities were paused due to COVID-19. 6 Due to a change in methodology in 2019, this data is not comparable to previous years. 7 All Healthy Lung Saudi Arabia activities were paused during 2020 due to COVID-19. 8 After limited activities in Q1, Healthy Lung Egypt programme was paused due to the conversion of healthcare facilities to COVID-19 isolation units. 9 The 2018 and 2019 cumulative numbers for our Young Health Programme have been restated. 10 The AstraZeneca HealthCare Foundation is a Delaware (United States) not-for-profit corporation and a 501(c)(3) entity, separate from AstraZeneca Pharmaceuticals, organised for charitable purposes including to promote public awareness and education of healthcare issues and support eligible non-profit organisations in alignment with its mission.

8 The Foundation has received $35 million in contributions to date from AstraZeneca to support the Connections for Cardiovascular HealthSM programme. All cumulative values are from 2009-2019. Self-reported data from Grant Awardees. 11 A number of different medicines are administered through the programme. This includes medicines donated by AstraZeneca as well as those procured using funds donated for the programme. 12 You can find out more about our approach in the AstraZeneca Affordability Statement. 13 These Patient Assistance Programmes use fully donated product without expectation of payment from the patient for any portion or to access the programme. 5 AstraZeneca Data Summary 2020 Environmental protectionEthics and transparencyAccess to healthcare5 TargetsHighlightsAPI resource efficiency2025 targetEnsure 90% of active pharmaceutical ingredient (API) syntheses meet resource efficiency targets at update Since 2015, 67% of projects (two of three) have met defined resource efficiency targets.

9 In 2020 a new oncology medicine met its Process Mass Intensity (PMI) target at launch and we achieved a PMI reduction of 9% across the late stage project portfolio. Status: LaggingBiologic product resource efficiency2020 targetDevelop resource efficiency targets for biologic update We set an internal PMI target for monoclonal antibody projects (our largest class of biological products). Status: AchievedSustainable sourcing2022 targetEnsure 95% of paper-based product packaging materials used are supplied from sustainable update Progress was made towards the target of 95%. Learn more about our use of commodities linked to deforestation in our new Forestry Statement. Status: LaggingSmall molecule API syntheses that meet resource efficiency at launch201850% 201950% 202067% Internal resource efficiency target set for biologic products2022 target:95% of paper-based product packaging are from sustainable sourcesKPIsResource efficiencySDG201820192020 Small molecule API syntheses that meet resource efficiency at environmental stewardship Environmental protectionEthics and transparencyAccess to healthcare6 AstraZeneca Data Summary 2020 Greenhouse gas reductionTargetsHighlightsGHG sites and fleet2025 target Eliminate Scope 1 and 2 emissions by end of update Reduced Scope 1 and 2 emissions by 60% since : On planRoad fleet electrification2025 target100% zero emissions road fleet by update Our electric vehicles fleet represents of our total fleet.

10 Status: On plan 60% reduction since 2015 Total Scope 1 and 2 emissions (tCO2e)2015 627,0212018 413,0872019 385,4872020 248,006 KPIsAmbition Zero Carbon 2025 (tonnes (t)CO2e)2015 baseline201820192020 Scope 12 295,2113272,7373254,4023224,771 Scope 2 - Market based4331,8113140,3503 131,085323,235 Total Scope 1 & 2 627,021413,087385,487 248,006 Scope 1 & 2 intensity (tCO2e per million USD of revenue)2519169 Scope 2 - Location based4, 5276,6633248,9843233,9513212,003 Outside of Scopes (CO2 of biological origin)2,8227,1786,6665,640 Road fleet electrification2015 Baseline201820192020 Total vehicles - leased17,23316,00216,33816,911 Percentage of leased hybrid vehicles 0%5%22%39%Percentage of leased vehicles that are PHEV0%1%3%7%EV100: Electric Vehicle fleet0% electric vehicles target set in 2020 AstraZeneca Data Summary 20207 Access to healthcareEnvironmental protectionEthics and transparencyGreenhouse gas reductionKPIsSite energy consumption and renewables2015 baseline201820192020 Total energy use (MWh)1,828,66131,850,98431,741,95531,595 ,330EP 100: Energy productivity (million USD per GWh total energy) energy electricity and heat (MWh)113,839557,947544,095699,649RE100.